A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections

Retina

Volumn 31, Issue 8, 2011, Pages 1449-1469

  Van Der Reis, Margriet I ^a   La Heij, Ellen C ^a   De Jong Hesse, Yvonne ^b   Ringens, Peter J ^b   Hendrikse, Fred ^a   Schouten, Jan S A G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adverse events; age related macular degeneration AMD; anti vascular endothelial growth factor anti VEGF; Avastin; bevacizumab; Lucentis; Macugen; pegaptanib; ranibizumab

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; WARFARIN;

ABDUCENS NERVE PARALYSIS; ANEMIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; APPENDIX PERFORATION; ARTHRALGIA; BACKACHE; BRADYCARDIA; BRONCHITIS; CATARACT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHEMOSIS; CHOROID HEMORRHAGE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HEMORRHAGE; CORNEA INJURY; DEEP VEIN THROMBOSIS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUODENUM ULCER; ENDOPHTHALMITIS; EPISTAXIS; EYE PAIN; GANGRENE; GLAUCOMA; HEADACHE; HEART FAILURE; HEART INFARCTION; HEMARTHROSIS; HEMATEMESIS; HEMATOCHEZIA; HEMATOMA; HEMATOTHORAX; HEMATURIA; HEMOPERITONEUM; HUMAN; HYPEREMIA; HYPERTENSION; INFLUENZA; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRITIS; LENS DISEASE; LIP DISEASE; MALLORY WEISS SYNDROME; METRORRHAGIA; MYOPIC FOVEOSCHISIS; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; PHOTODYNAMIC THERAPY; PUNCTATE KERATITIS; RECTUM HEMORRHAGE; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA TEAR; RETINOSCHISIS; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRACTION RETINA DETACHMENT; TRANSIENT GLOBAL AMNESIA; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; UVEITIS; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; VITREOUS DISEASE; VITREOUS FLOATERS; VITRITIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052512394     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182278ab4     Document Type: Review

References (304)

1. Food and Drug Administration. Label Macugen (Pegaptanib sodium) FDA application no. (NDA) 021756. Eyetech INC. Available at: Http://www.accessdata. fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=search.label- ApprovalHistory. Accessed February 19, 2009.
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16. (Pubitemid 40051904)
3. Food and Drug Administration. Highlights of prescribing information Lucentis. Genentech. Available atwww.accessdata. fda.gov/drugsatfda-docs/label/ 2006/125156lbl.pdf. Accessed February 19, 2009.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335. (Pubitemid 41073112)
6. Food and Drug Administration. Label Avastin. Genentech. Available at: Www.accessdata.fda.gov/drugsatfda-docs/label/ 2009/125085s0168lbl.pdf. Accessed February 19, 2009.
7. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11.
8. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400.
9. Golder S, McIntosh HM, Duffy S, Glanville J. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J 2006;23:3-12.
10. Loke YC, Price D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2008. Version 5.0.1. Updated September 2008.
11. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2008. Version 5.0.1. Updated September 2008.
12. Online software Clopper-Pearson confidence interval.Available at: Http://statpages.org/confint.html. Accessed November 18, 2010.
13. World Health Organization. Safety of medicines: A guide to detecting and reporting adverse drug reactions. Geneva, Switzerland: World Health Organization; 2002.
14. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
15. Aggio FB, Farah ME, de Melo GB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007;21:408-409. (Pubitemid 46358806)
16. Alkuraya HS, Al Kharashi AS, Alharthi E, Chaudhry IA. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol 2008;29:411-413.
17. Amselem L, Diaz Llopis M, Garcia Delpech S, et al. Papulopustular eruption after intravitreal bevacizumab (Avastin). Acta Ophthalmol 2009;87:110-111.
18. Arias L, Caminal JM, Rubio M, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol 2007;17:992-995. (Pubitemid 351262915)
19. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:779-781.
20. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008;28:996-1001.
21. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: An old problem in a new era. Retina 2007;27:523-534. (Pubitemid 46905141)
22. Bakri SJ, Patel SP. Retinal pigment epithelial tear following intravitreal bevacizumab. Eye 2007;21:424-425. (Pubitemid 46358811)
23. Forooghian F, Cukras C, Chew EY. Retinal angiomatous proliferation complicated by pigment epithelial tear following intravitreal bevacizumab treatment. Can J Ophthalmol 2008; 43:246-248. (Pubitemid 351518187)
24. Gamulescu MA, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007; 245:1037-1040.
25. Gelisken F, Ziemssen F, Voelker M, Bartz Schmidt KU. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol Scand 2006;84:833-834. (Pubitemid 44688343)
26. Neri P, Mariotti C, Mercanti L, et al. Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 2008;28:425-427.
27. Hannan SR, Madhusudhana KC, Lotery AJ, Newsom RS. Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration. Br J Ophthalmol 2007;91:977-978. (Pubitemid 47013117)
28. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye 2007;21:1541.
29. Mathews JP, Jalil A, Lavin MJ, Stanga PE. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin): Optical coherence tomography and fluorescein angiographic findings. Eye 2007;21:1004-1005. (Pubitemid 47062092)
30. Meyer CH, Mennel S, Horle S, Schmidt JC. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007;143:169-170. (Pubitemid 44917816)
31. Mitamura Y, Ogata K, Oshitari T, et al. Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:717-718. (Pubitemid 351684190)
32. Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006;90:1207-1208. (Pubitemid 44351161)
33. Shah CP, Hsu J, Garg SJ, et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006;142:1070-1072.
34. Schaal KB, Hoh AE, Scheuerle A, Dithmar S. Endophthalmitis after repeated bevacizumab injections [in German]. Ophthalmologe 2008;106:356-358.
35. Byeon SH, Kwon OW, Lee SC. Transient global amnesia following intravitreal injection of bevacizumab. Acta Ophthalmol 2009;87:570.
36. Subramanyam A, Phatak S, Chudgar D. Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment. Indian J Ophthalmol 2007;55:483-486.
37. Park HJ, Guy J. Sixth nerve palsy post intravitreal bevacizumab for AMD: A new possibly causal relationship and complication? Binocul Vis Strabismus Q 2007;22:209.
38. Kawashima M, Mori R, Mizutani Y, Yuzawa M. Choroidal folds and retinal pigment epithelium tear following intravitreal bevacizumab injection for exudative agerelated macular degeneration. Jpn J Ophthalmol 2008;52: 142-144. (Pubitemid 351624409)
39. Jonas JB, Schmidbauer M, Rensch F. Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol 2008;87:571-572.
40. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008;86:925-927.
41. Kopel AC, Carvounis PE, Holz ER. Bacillus cereus endophthalmitis following intravitreous bevacizumab injection. Ophthalmic Surg Lasers Imaging 2008;39:153-154. (Pubitemid 351619795)
42. Maier M, Feucht N, Lanzl I, et al. Retinochoroidopathy after intravitreal anti-VEGF treatment [in German]. Ophthalmologe 2008;106:729-734.
43. Mennel S, Callizo J, Schmidt JC, Meyer CH. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 2007;85:689-691. (Pubitemid 47316777)
44. Nicolo M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol 2006;16:770-773. (Pubitemid 44870767)
45. Peng CH, Cheng CK, Chiou SH. Retinal pigment epithelium tear after intravitreal bevacizumab injection for polypoidal choroidal vasculopathy. Eye 2009;23:2126-2129.
46. Pieramici DJ, Avery RL, Castellarin AA, et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006;26:841-842. (Pubitemid 44386116)
47. Rodrigues EB, Shiroma H, Meyer CH, et al. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007;85:915-916.
48. Sayanagi K, Ikuno Y, Soga K, et al. Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol 2008;87:460-463.
49. Tranos P, Gemenetzi M, Papandroudis A, et al. Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin. Eye 2008;22:862. (Pubitemid 351850529)
50. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363. (Pubitemid 351733229)
51. Hasler S, Schmid MK, Becht CN. Acute anterior nongranulomatous uveitis after intravitreal injection of bevacizumab [in German]. Klin Monatsbl Augenheilkd 2008;225:446-447. (Pubitemid 352016480)
52. Chieh JJ, Fekrat S. Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. Ann Ophthalmol (Skokie) 2007;39:51-52. (Pubitemid 350022306)
53. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007;35:494-496. (Pubitemid 47162770)
54. Gibran SK, Sachdev A, Stappler T, et al. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol 2007;91:602-604. (Pubitemid 46716525)
55. Montero JA, Ruiz Moreno JM, De La Vega C. Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema. Eur J Ophthalmol 2008; 18:469-472.
56. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-1063.
57. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009;40:68-70.
58. Amselem L, Pulido JS, Diaz Llopis M, et al. Retinal pigment epithelial tear following ranibizumab use. Eye 2007;21:846-847. (Pubitemid 46909199)
59. Apte RS. Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD. Int Ophthalmol 2007;27:59-61. (Pubitemid 46672149)
60. Bakri SJ, Kitzmann AS. Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007;143:505-507. (Pubitemid 46273349)
61. Carvounis PE, Kopel AC, Benz MS. Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol 2007;143:504-505.
62. Kiss C, Michels S, Prager F, et al. Retinal pigment epithelium tears following intravitreal ranibizumab therapy. Acta Ophthalmol Scand 2007;85:902-903. (Pubitemid 350142817)
63. Lee GK, Lai TY, Chan WM, Lam DS. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:1225-1227. (Pubitemid 47034347)
64. Querques G, Souied EH, Soubrane G. Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol 2009;87:235-237.
65. Somner JE, Mansfield D. Inadvertent injection of intravitreal air during intravitreal Lucentis injection for wet age-related macular degeneration: An undescribed complication. Eye 2009;23:1744.
66. Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007;17:674-676. (Pubitemid 351175350)
67. Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006;141:752-754.
68. Singh RP, Sears JE. Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration. Am J Ophthalmol 2006;142:160-162. (Pubitemid 43946807)
69. Chang LK, Flaxel CJ, Lauer AK, Sarraf D. RPE tears after pegaptanib treatment in age-related macular degeneration. Retina 2007;27:857-863. (Pubitemid 47479380)
70. Chen E, Ho AC, Garg SJ, et al. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging 2009;40:192-194.
71. Kocabora MS, Ozbilen KT, Serefoglu K. Intravitreal silicone oil droplets following pegaptanib injection. Acta Ophthalmol 2010;88:e44-e45.
72. Steffensmeier AC, Azar AE, Fuller JJ, et al. Vitreous injections of pegaptanib sodium triggering allergic reactions. Am J Ophthalmol 2007;143:512-513.
73. Krishnan R, Goverdhan S, Lochhead J. Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye 2009;23: 1238-1239.
74. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-958.
75. Rasier R, Artunay O, Yuzbasioglu E, et al. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 2009;23:1714-1718.
76. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections. Retina 2009;29: 313-318.
77. Wong LJ, Desai RU, Jain A, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28:1151-1158.
78. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008;22:590-591. (Pubitemid 351560425)
79. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349. (Pubitemid 44702055)
80. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-376.
81. Wu L, Martinez Castellanos MA, Quiroz Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
82. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007;27:535-540. (Pubitemid 46905142)
83. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
84. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567. (Pubitemid 351589565)
85. Kook D, Wolf A, Neubauer AS, et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress [in German]. Ophthalmologe 2008;105:158-164.
86. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-881. (Pubitemid 44547439)
87. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23:240-242. (Pubitemid 46986604)
88. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
89. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2008;92:210-212. (Pubitemid 351224096)
90. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27:541-551. (Pubitemid 46905143)
91. Ziemssen F, Zhu Q, Peters S, et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: Preliminary findings of a pilot study. Int Ophthalmol 2009;29:213-224.
92. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007;85:119-120. (Pubitemid 46140172)
93. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 2007;27:1044-1047. (Pubitemid 350304005)
94. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216. (Pubitemid 351224097)
95. Ziemssen F, Warga M, Neuhann IM, et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? Br J Ophthalmol 2006;90:922. (Pubitemid 43974012)
96. Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: Comparison of different treatments. Eye 2009;23:2163-2168.
97. Meyer CH, Mennel S, Eter N. Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application [in German]. Ophthalmologe 2007;104:952-957.
98. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
99. Gelisken F, Ziemssen F, Voelker M, et al. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye 2009;23:694-702.
100. Garg S, Brod R, Kim D, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative agerelated macular degeneration. Clin Experiment Ophthalmol 2008;36:252-256. (Pubitemid 351560274)
101. Weinberger AW, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007;144: 294-296. (Pubitemid 47094707)
102. Spandau UH, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006;142:1068-1070. (Pubitemid 44853878)
103. Shaikh S, Olson JC, Richmond PP. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Indian J Ophthalmol 2007; 55:470-472.
104. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.
105. Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009;23:2187-2193.
106. Chiang A, Chang LK, Yu F, Sarraf D. Predictors of anti- VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008;28:1265-1269.
107. Dayani PN, Siddiqi OK, Holekamp NM. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 2007;144:451-453. (Pubitemid 47331391)
108. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006;141:200-201. (Pubitemid 43016199)
109. Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2007;143:1034-1035. (Pubitemid 46764645)
110. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431. (Pubitemid 46624281)
111. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93: 457-462.
112. Smith BT, Kraus CL, Apte RS. Retinal pigment epithelial tears in ranibizumab-treated eyes. Retina 2009;29: 335-339.
113. Mojica G, Hariprasad SM, Jager RD, Mieler WF. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 2008;92:584. (Pubitemid 351498004)
114. Freund KB, Laud K, Eandi CM, Spaide RF. Silicone oil droplets following intravitreal injection. Retina 2006;26:701-703. (Pubitemid 44620379)
115. Angulo Bocco MC, Glacet Bernard A, Zourdani A, et al. Intravitreous injection: Retrospective study on 2028 injections and their side effects [in French]. J Fr Ophtalmol 2008;31: 693-698.
116. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007;245:215-220. (Pubitemid 46291451)
117. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93.e1.
118. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:941-948. (Pubitemid 46979534)
119. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86:482-489.
120. Abraham Marin ML, Cortes Luna CF, Alvarez Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: A pilot study. Graefes Arch Clin Exp Ophthalmol 2007;245:651-655.
121. Pournaras JA, Nguyen C, Vaudaux JD, et al. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): Preliminary results [in German]. Klin Monatsbl Augenheilkd 2008;225:397-400. (Pubitemid 352016466)
122. Valmaggia C, Niederberger H, Lang C, et al. The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin) [in German]. Klin Monatsbl Augenheilkd 2008;225:380-384. (Pubitemid 352016463)
123. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. Am J Ophthalmol 2009;147:94-100.e1.
124. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
125. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
126. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008;52:52-56. (Pubitemid 351462226)
127. Maier M, Feucht N, Haas K, et al. Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV) [in German]. Klin Monatsbl Augenheilkd 2008;225:818-824.
128. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007; 144:886-892.
129. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9. (Pubitemid 43946791)
130. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 2008;145:249-256.
131. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-1361. (Pubitemid 47606600)
132. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study. Am J Ophthalmol 2007;143:510-512.
133. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007;27:445-450. (Pubitemid 46624284)
134. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008;22:82-86.
135. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578. (Pubitemid 46579387)
136. Ehrlich R, Weinberger D, Priel E, Axer Siegel R. Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity. Retina 2008;28: 1302-1307.
137. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444. (Pubitemid 46624283)
138. Falkenstein IA, Cheng L,Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007;27:701-706. (Pubitemid 47051765)
139. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998. (Pubitemid 44973217)
140. Gunduz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye 2008; 22:1168-1171.
141. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration [in German]. Ophthalmologe 2007;104:588-593.
142. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185. (Pubitemid 46829388)
143. IturraldeD,SpaideRF,MeyerleCB, et al. Intravitrealbevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 2006;26:279-284. (Pubitemid 44318180)
144. Ghazi NG, Knape RM, Kirk TQ, et al. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina 2008;28:689-695. (Pubitemid 351655120)
145. Gomi F, Nishida K, Oshima Y, et al. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 2007;143:507-510.
146. Arevalo JF,Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009;23:117-123.
147. Pedersen R, Soliman W, Lund Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007;85:526-533. (Pubitemid 47163114)
148. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68-73. (Pubitemid 46766732)
149. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-1322. (Pubitemid 47492865)
150. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: Results from 118 cases. Br J Ophthalmol 2007;91:1716-1717. (Pubitemid 350207411)
151. Mandal S, Garg S, Venkatesh P, et al. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007;125:1487-1492. (Pubitemid 350106680)
152. Sacu S, Stifter E, Vecsei Marlovits PV, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye 2008;23:1404-1410.
153. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: Efficacy of three consecutive monthly injections. Am J Ophthalmol 2008;146:91-95.
154. Ozkiris A. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema. Eye 2009;23:616-620.
155. Geitzenauer W, Michels S, Prager F, et al. Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration [in German]. Klin Monatsbl Augenheilkd 2006;223:822-827. (Pubitemid 44860922)
156. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-termsafety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511. (Pubitemid 44620390)
157. Schaal KB, Engler C, Schutt F, et al. Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD [in German]. Ophthalmologe 2008;105:538-543.
158. Ach T, Dawczynski J, Konigsdorffer E, et al. Subjective sensations after intravitreal injection of bevacizumab [in German]. Klin Monatsbl Augenheilkd 2007;224:180-184. (Pubitemid 46739635)
159. Jonas JB, Libondi T, von Baltz S, Vossmerbaeumer U. Intravitreal bevacizumab for vitreous haemorrhage. Acta Ophthalmol 2008;86:585-586.
160. Fish GE. Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:276-300.
161. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009;23:2042-2045.
162. Adan A, Mateo C, Navarro R, et al. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-1186. (Pubitemid 350211522)
163. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-983.
164. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 2009;23:2223-2227.
165. Iliev ME, Domig D, Wolf Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056. (Pubitemid 44853889)
166. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2009;87:77-81.
167. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606.
168. Song JH, Byeon SH, Lee SC, et al. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009;223:85-92.
169. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008;145:8756.
170. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126. (Pubitemid 46963178)
171. Hayashi K, Ohno Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009;247:609-618.
172. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008;146:410-416.
173. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748-755.
174. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160. (Pubitemid 46202862)
175. Rheaume MA, Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008;43:576-580.
176. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165. (Pubitemid 46202863)
177. Costagliola C, Cipollone U, Rinaldi M, et al. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: A survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol 2008;66:667-673.
178. Paccola L,Costa RA, FolgosaMS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
179. Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661-666. (Pubitemid 351684177)
180. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008;28:1314-1318.
181. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-355. (Pubitemid 351363529)
182. Andrijevic Derk B, Vatavuk Z, Bencic G, et al. Intravitreal bevacizumab for neovascular glaucoma. Acta Clin Croat 2008;47:175-179.
183. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70-73.
184. Finger RP, Charbel Issa P, Ladewig M, et al. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 2008;92:483-487. (Pubitemid 351497973)
185. Krebs I, Lie S, Stolba U, et al. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2009;87:611-617.
186. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 2009;223:124-127.
187. Rensch F, Spandau UH, Wickenhauser A, Jonas JB. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol 2010;88: E36-e37.
188. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-Month results. Br J Ophthalmol 2008;92:1035-1039.
189. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
190. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
191. Chang LK, Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945. (Pubitemid 352008374)
192. Pedersen KB, Sjolie AK, Moller F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol 2009;87:714-719.
193. McGimpsey SJ, Gillies MC. Treatment of macular degeneration- controversy and hope. Br J Ophthalmol 2008;92:436-437. (Pubitemid 351363557)
194. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489. (Pubitemid 351447960)
195. Chung EJ, Hong YT, Lee SC, et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241-1247.
196. Barone A, Russo V, Prascina F, Delle Noci N. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina 2009;29:33-37.
197. Jaissle GB, Leitritz M, Gelisken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27-33.
198. Mandal S, Venkatesh P, Abbas Z, et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2007;245:1825-1829. (Pubitemid 350154017)
199. Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008;246: 1699-1705.
200. Tran TH, Fardeau C, Terrada C, et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008;246:1685-1692.
201. Lam DS, Lai TY, Lee VY, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina 2009;29:292-299.
202. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009;29: 319-324.
203. Joeres S, Heussen FM, Treziak T, et al. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007;245: 1597-1602. (Pubitemid 47491546)
204. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436. (Pubitemid 47423323)
205. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007;245:917-918. (Pubitemid 46805628)
206. Neri P, Salvolini S, Mariotti C, et al. Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol 2009;93:155-158.
207. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-1195. (Pubitemid 350211523)
208. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
209. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005. (Pubitemid 44973218)
210. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-1013. (Pubitemid 44973219)
211. Ruiz Moreno JM, Montero JA, Gomez Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
212. Bhatnagar P, Freund KB, Spaide RF, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2007;27:897-902. (Pubitemid 47479384)
213. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
214. RussoV, Barone A, Conte E, et al. Bevacizumab comparedwith macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 2009;29:511-515.
215. Hernandez Rojas ML, Quiroz Mercado H, DalmaWeiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
216. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 2007;27:1013-1019. (Pubitemid 350304000)
217. Mason JO III, Albert MA Jr, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 2007;27: 903-907. (Pubitemid 47479385)
218. Wiegand TW, Rogers AH, McCabe F, et al. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br J Ophthalmol 2009;93:47-51.
219. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 2007;27:451-457. (Pubitemid 46624285)
220. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: Six-month results of a prospective trial. Retina 2007;27:1004-1012. (Pubitemid 350303999)
221. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27: 419-425. (Pubitemid 46624280)
222. Mirshahi A, Namavari A, Djalilian A, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behcet disease. Ocul Immunol Inflamm 2009;17:59-64.
223. Yuzbasioglu E, Artunay O, Rasier R, et al. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr Eye Res 2009;34:231-237.
224. Astam N, Batioglu F, Ozmert E. Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmol 2009;29:343-348.
225. Kovacevic D, Caljkusic Mance T, Misljenovic T, et al. Intravitreal bevacizumab for the management of age-related macular degeneration. Coll Antropol 2008;32(suppl 2):5-7.
226. Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008;28:957-963.
227. Beutel J, Ziemssen F, Luke M, et al. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: One-year results. Int Ophthalmol 2010;30:15-22.
228. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study. Retina 2008;28:41-45.
229. Mintz Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28: 831-838.
230. Quiroz Mercado H, Martinez Castellanos MA, Hernandez Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28: S19-S25.
231. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17:620-626. (Pubitemid 47605773)
232. Schaal KB, Hoh AE, Scheuerle A, et al. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion [in German]. Ophthalmologe 2007;104:285-289.
233. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-1579.e1.
234. De Clercq C, Snyers B, Guagnini AP, Kozyreff A. Treatment of age-related macular degeneration with intravitreous injections of bevacizumab (Avastin): Short-term results [in French]. Bull Soc Belge Ophtalmol 2007:15-21.
235. Lazic R, Gabric N, Dekaris I, et al. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 2007;31(suppl 1):77-81.
236. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219. (Pubitemid 351643150)
237. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-154.
238. Wolf A, Kook D, Kreutzer T, et al. Anti-VEGF treatment for retinal angiomatous proliferation [in German]. Ophthalmologe 2008;105:845-851.
239. Fang X, Sakaguchi H, Gomi F, et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008;86:800-805.
240. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-e15.
241. Jaissle GB, Ziemssen F, Petermeier K, et al. Bevacizumab for treatment of macular edema secondary to retinal vein occlusion [in German]. Ophthalmologe 2006;103:471-475. (Pubitemid 43892185)
242. Dithmar S, Schaal KB, Hoh AE, et al. Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia [in German]. Ophthalmologe 2009;106:527-530.
243. Lee SY, Kim JG, Joe SG, et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008;22:92-99.
244. Spitzer MS, Ziemssen F, Yoeruek E, et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008;34:70-75. (Pubitemid 350299767)
245. Ornek K, Ornek N. Intravitreal bevacizumab treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2008;24:403-407.
246. Byeon SH, Kwon YA, Oh HS, et al. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther 2007;23:387-394. (Pubitemid 350195064)
247. Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol 2009;29:349-357.
248. Finger PT. Radiation retinopathy is treatable with antivascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008;70:974-977. (Pubitemid 351296131)
249. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007;55:451-455.
250. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571-80, 80.e1-e3.
251. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008;86:365-371.
252. Minnella AM, Savastano CM, Ziccardi L, et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008;86:683-687.
253. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-948.
254. Furino C, Boscia F, Recchimurzo N, et al. Intravitreal bevacizumab for treatment-naive subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2009;87:404-407.
255. Jiang Y, Liang X, Li X, et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009;87:736-740.
256. Abegg M, Tappeiner C, Wolf Schnurrbusch U, et al. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008;8:18.
257. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular agerelated macular degeneration. Am J Ophthalmol 2007;143: 566-583.
258. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969.
259. Rothenbuehler SP,Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-837.
260. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
261. Eldaly MA, Styles C. First versus second eye intravitreal ranibizumab therapy for wet AMD. Retina 2009;29:325-328.
262. Konstantinidis L, Mantel I, Pournaras JA, et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:311-318.
263. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
264. Bolz M, Ritter M, Polak K, et al. The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD [in German]. Ophthalmologe 2008;105: 650-5.
265. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115: E47-e54.
266. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration. A Phase I/II Multicenter, Controlled, Multidose Study. Ophthalmology 2006;113:633-642.
267. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-799. (Pubitemid 351426182)
268. Reche Frutos J, Calvo Gonzalez C, Donate Lopez J, et al. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol 2008;18: 645-648.
269. Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 2008;222:321-323.
270. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623.e1.
271. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053. (Pubitemid 40797460)
272. Lommatzsch AP, Heimes B, Gutfleisch M, et al. Treatment of vascularised serous pigment epithelium detachment in AMDobservations after changing the intravitreal agent due to lack of response [in German]. Klin Monatsbl Augenheilkd 2008; 225:874-879.
273. Kloos P, Bernasconi P, Estermann S, et al. Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration [in German]. Klin Monatsbl Augenheilkd 2008;225:385-391. (Pubitemid 352016464)
274. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712. (Pubitemid 44442451)
275. Rouvas AA, Papakostas TD, Vavvas D, et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: A prospective study. Retina 2009;29:536.
276. Silva RM, Ruiz Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
277. Rensch F, Spandau UH, Schlichtenbrede F, et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008;39:182-185. (Pubitemid 351947661)
278. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to agerelated macular degeneration: 6-month results of an openlabel uncontrolled clinical study. Eur J Ophthalmol 2007;17: 230-237. (Pubitemid 46918110)
279. Maier M, Feucht N, Huebner M, Lohmann C. Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib [in German]. Klin Monatsbl Augenheilkd 2008;225:582-587. (Pubitemid 352016672)
280. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113: 992-1001.e6.
281. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
282. Guyer DR, Fish G, Haller JA, et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003;110:979-986. (Pubitemid 36560500)
283. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114:1702-1712.
284. Martin DF, Klein M, Haller J, et al. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152. (Pubitemid 36125089)
285. Emerson GG, Flaxel CJ, Lauer AK, et al. Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration. Retina 2007;27:724-729. (Pubitemid 47051767)
286. Ehlers JP, Fintak DR, Gupta OP, et al. Pegaptanib for choroidal neovascularization in treatment-naive exudative age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2007;38:371-377. (Pubitemid 350057917)
287. Quiram PA, Hassan TS, Williams GA. Treatment of naive lesions in neovascular age-related macular degeneration with pegaptanib. Retina 2007;27:851-856. (Pubitemid 47479379)
288. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-1611.
289. Atmani K, Coscas F, Coscas G, Soubrane G. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: A prospective case series. Eye 2008;23:1150-1154.
290. Lopez Guajardo L, Del Valle FG, Moreno JP, Teus MA. Reduction of pegaptanib loss during intravitreal delivery using an oblique injection technique. Eye 2008;22:430-433. (Pubitemid 351404471)
291. Mahmood S, Kumar N, Lenfestey PM, et al. Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: A retrospective review. Eye 2009;23:530-535.
292. Aronson JK. Side effects of drugs Annual 31. Oxford, UK; 2009.
293. Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol 1981;65:417-422. (Pubitemid 11046373)
294. Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993;111: 831-836.
295. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: A comprehensive review. Retina 2004; 24:676-698. (Pubitemid 39391758)
296. Lloyd Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-486.
297. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-1846.
298. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-625. (Pubitemid 46625484)
299. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182. (Pubitemid 350181137)
300. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859. (Pubitemid 46635858)
301. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27: 1260-1266. (Pubitemid 350211535)
302. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: The Blue Mountains Eye Study. Ophthalmology 2007;114:1143-1150. (Pubitemid 46829381)
303. Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008;92:509-512. (Pubitemid 351497979)
304. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004;328:39-41. (Pubitemid 38067746)